The Effects of Vasopressin on Attention Control

Healthy Clinical Trial

Official title:

The Effects of Vasopressin on Attention Control: An Eye-tracking Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04493554
• Other study ID #: UESTC-neuSCAN-70
• Status: Completed
• Phase: N/A
• Start date: July 28, 2020
• Est. completion date: January 1, 2021

Study information

• Verified date: January 2021
• Source: University of Electronic Science and Technology of China
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main aim of the present study is to investigate whether intranasal vasopressin (20IU) could influence attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Description:

A number of previous studies have reported vasopressin's effect on human social behavior and social cognition, although it remains unclear whether vasopressin could modulate attention allocation including stimulus-driven bottom-up control and goal-directed top-down control. In the current randomized, between-subject, placebo controlled study, 89 healthy male subjects will be recruited and receive either vasopressin (20 IU) or placebo control administered intranasally. 45 minutes after treatment subjects will be required to complete a social-emotional saccade /antisaccade eye-tracking paradigm. The paradigm uses social (happy, sad, angry, fear, and neutral faces) as well as non-social (oval shapes) stimuli to explore social- and emotion-specific effects of vasopressin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 89
• Est. completion date: January 1, 2021
• Est. primary completion date: November 30, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Healthy participants

• Non smokers

Exclusion Criteria:

• Previous or current medical, psychiatric, neurological disorder

• Regular medication

• Use of any psychoactive substances in the 24 hours before experiment

• Contra-indications for vasopressin

• Contra-indications for eye-tracking data acquisition

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Vasopressin
Administration of vasopressin (20 IU) intranasally
• Placebo
Administration of placebo intranasally

Locations

Country	Name	City	State
China	University of Electronic Science and Technology of China(UESTC)	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
University of Electronic Science and Technology of China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect of vasopressin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli	Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions	45 minutes - 100 minutes after treatment
Primary	Effect of vasopressin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli	Comparison between social-specific error rates of saccade/antisaccade between the vasopressin and placebo treatment conditions	45 minutes - 100 minutes after treatment
Secondary	Emotion-specific effects of vasopressin administration on saccade/antisaccade latencies towards the separate facial emotions	Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions	45 minutes - 100 minutes after treatment
Secondary	Emotion-specific effects of vasopressin administration on saccade/antisaccade error rates for the separate facial emotions	Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin and placebo treatment conditions	45 minutes - 100 minutes after treatment